277 related articles for article (PubMed ID: 38338658)
1. γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy.
Papadakos SP; Arvanitakis K; Stergiou IE; Koutsompina ML; Germanidis G; Theocharis S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338658
[TBL] [Abstract][Full Text] [Related]
2. The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner.
Yi Y; He HW; Wang JX; Cai XY; Li YW; Zhou J; Cheng YF; Jin JJ; Fan J; Qiu SJ
J Hepatol; 2013 May; 58(5):977-83. PubMed ID: 23262246
[TBL] [Abstract][Full Text] [Related]
3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
4. Low counts of γδ T cells in peritumoral liver tissue are related to more frequent recurrence in patients with hepatocellular carcinoma after curative resection.
Cai XY; Wang JX; Yi Y; He HW; Ni XC; Zhou J; Cheng YF; Jin JJ; Fan J; Qiu SJ
Asian Pac J Cancer Prev; 2014; 15(2):775-80. PubMed ID: 24568494
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma-infiltrating γδ T cells are functionally defected and allogenic Vδ2
He W; Hu Y; Chen D; Li Y; Ye D; Zhao Q; Lin L; Shi X; Lu L; Yin Z; He X; Gao Y; Wu Y
Clin Transl Med; 2022 Apr; 12(4):e800. PubMed ID: 35390227
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou I; Kalafateli M; Triantos C
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473878
[TBL] [Abstract][Full Text] [Related]
7. γδ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways.
Jiang H; Yang Z; Song Z; Green M; Song H; Shao Q
Int Immunopharmacol; 2019 May; 70():167-173. PubMed ID: 30802679
[TBL] [Abstract][Full Text] [Related]
8. The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture.
Hoh A; Dewerth A; Vogt F; Wenz J; Baeuerle PA; Warmann SW; Fuchs J; Armeanu-Ebinger S
Liver Int; 2013 Jan; 33(1):127-36. PubMed ID: 23088518
[TBL] [Abstract][Full Text] [Related]
9. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
Wang J; Ling S; Ni J; Wan Y
BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
[TBL] [Abstract][Full Text] [Related]
10. Identification of new potential antigen recognized by γδT cells in hepatocellular carcinoma.
Xi X; Guo Y; Zhu M; Qiu F; Lei F; Li G; Du B
Cancer Immunol Immunother; 2021 Jul; 70(7):1917-1927. PubMed ID: 33399933
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
[TBL] [Abstract][Full Text] [Related]
12. [Hepatic stellate cells inhibit the proliferation and invasion of HepG2 hepatocellular carcinoma via activating γδ T cells].
Fan K; Liao R; Xie Y; Peng C; Du C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jul; 33(7):870-874. PubMed ID: 28712391
[TBL] [Abstract][Full Text] [Related]
13. Application of adoptive cell therapy in hepatocellular carcinoma.
Wu D; Li Y
Immunology; 2023 Dec; 170(4):453-469. PubMed ID: 37435926
[TBL] [Abstract][Full Text] [Related]
14. γδ T cells: The potential role in liver disease and implications for cancer immunotherapy.
Ren H; Li W; Liu X; Zhao N
J Leukoc Biol; 2022 Dec; 112(6):1663-1668. PubMed ID: 36098208
[TBL] [Abstract][Full Text] [Related]
15. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
Guizhen Z; Guanchang J; Liwen L; Huifen W; Zhigang R; Ranran S; Zujiang Y
Front Endocrinol (Lausanne); 2022; 13():918869. PubMed ID: 36093115
[TBL] [Abstract][Full Text] [Related]
16. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Bozward AG; Warricker F; Oo YH; Khakoo SI
Front Immunol; 2021; 12():643310. PubMed ID: 33995362
[TBL] [Abstract][Full Text] [Related]
17. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.
Alexander AA; Maniar A; Cummings JS; Hebbeler AM; Schulze DH; Gastman BR; Pauza CD; Strome SE; Chapoval AI
Clin Cancer Res; 2008 Jul; 14(13):4232-40. PubMed ID: 18594005
[TBL] [Abstract][Full Text] [Related]
18. The capability of heterogeneous γδ T cells in cancer treatment.
Yan W; Dunmall LSC; Lemoine NR; Wang Y; Wang Y; Wang P
Front Immunol; 2023; 14():1285801. PubMed ID: 38077392
[TBL] [Abstract][Full Text] [Related]
19. γδ T cells: origin and fate, subsets, diseases and immunotherapy.
Hu Y; Hu Q; Li Y; Lu L; Xiang Z; Yin Z; Kabelitz D; Wu Y
Signal Transduct Target Ther; 2023 Nov; 8(1):434. PubMed ID: 37989744
[TBL] [Abstract][Full Text] [Related]
20. Human gamma-delta (γδ) T cell therapy for glioblastoma: A novel alternative to overcome challenges of adoptive immune cell therapy.
Choi H; Kim TG; Jeun SS; Ahn S
Cancer Lett; 2023 Sep; 571():216335. PubMed ID: 37544475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
